Thursday 14 May 2020

Dear Colleague,

The national flu immunisation programme 2020/21

1. Thank you for all the hard work everyone is doing as part of the NHS response to the global COVID-19 pandemic. It is more important than ever that we have effective plans in place for the 2020/21 flu season to protect those at risk, prevent ill-health and minimise further impact on the NHS and social care.

2. We recognise that delivering the flu immunisation programme is likely to be more challenging because of the impact of COVID-19 on our health and social care services. Further guidance will be issued about how to manage the immunisation programme to reflect circumstances nearer the planned start of the programme in September 2020. Discussions to consider expansion of the flu programme for this autumn are underway, and we will write again with any changes in due course.

3. In the meantime, you should continue to plan for the programme as usual. This letter is to inform you which groups are eligible for flu vaccination this autumn and sets out actions that you can take now to prepare for this autumn’s vaccination campaign.

4. In particular, this season it will be more important than ever to ensure that sufficient stocks of the recommended adult flu vaccines have been ordered for your eligible patients. In light of COVID-19, we ask Primary Care providers (General Practices and Community Pharmacies) to urgently review your vaccine orders now to make sure the number of vaccines ordered meet at least national ambitions and previous uptakes rates, whichever is highest. Please do so across your local Primary Care Network ensuring that the Clinical Commissioning Group flu lead is fully appraised of the position. If necessary, you may need to adjust your orders with suppliers.

5. For NHS Trusts and across Integrated Care System arrangements, please review your vaccine orders now to make sure the number of vaccines ordered meets your requirements for a vaccination programme to cover all frontline healthcare workers.
Eligibility

6. In 2020/21 groups eligible for the NHS funded flu vaccination programme are the same as last year, although this may change if the programme is expanded, and include:

- all children aged 2 to 10 (but not 11 years or older) on 31 August 2020
- those aged 6 months to under 65 years in clinical risk groups
- pregnant women
- those aged 65 years and over
- those in long-stay residential care homes
- carers
- close contacts of immunocompromised individuals
- health and social care staff employed by a registered residential care/nursing home, registered domiciliary care provider or a voluntary managed hospice provider

7. We expect universal vaccination of health and care workers and further guidance will be published in due course.

Prioritising flu vaccine uptake

8. Flu vaccination is one of the most effective interventions we have to reduce pressure on the health and social care system this winter. We are currently seeing the impact of COVID-19 on the NHS and social care, and this coming winter we may be faced with co-circulation of COVID-19 and flu. We understand that planning this year is more challenging with the uncertainties of staff absences, and how long policies around social distancing and school closures will remain in place. However, it is more important than ever to make every effort to deliver flu vaccination.

9. Those most at risk from flu are also most vulnerable to COVID-19. We must do all we can to help protect them this winter. We anticipate that concerns about COVID-19 may increase demand for flu vaccination in all groups this year, and some in at risk groups may have concerns about maintaining social distancing when being given the vaccine.

10. All those eligible should be given flu vaccination as soon as possible so that individuals are protected when flu begins to circulate. Providers should aim to schedule their immunisation services to match vaccine supply, usually from September, and complete vaccination by the end of November, where possible.
Service specifications

11. The Directed Enhanced Service (DES) specification for seasonal influenza and pneumococcal immunisation sets out all eligible groups for vaccination (apart from those aged two and three on 31 August 2020). It includes eligible frontline health and care workers working in residential care and nursing homes, domiciliary care providers and the voluntary managed hospice sector. The DES can be found at: www.england.nhs.uk/gp/investment/gp-contract/

12. There is a separate Enhanced Service (ES) specification for the childhood seasonal influenza vaccination programme, covering the vaccination of children aged 2 and 3 years on 31 August 2020. The ES can be found at: www.england.nhs.uk/gp/investment/gp-contract/

13. General practices are reminded that both the DES and ES specifications require a proactive call and recall system to contact all at risk patients. Various methods for this should be considered such as letter, email, phone call, text or social media and during face to face interactions if the opportunity arises, to encourage people to attend for their vaccination.

14. GP practices should also proactively call 2- and 3-year-olds. This year the national Childhood Health Information System (CHIS) service specification has been revised to include issuing an early communication to advise parents/carers of all eligible 2- and 3-year-olds that they should access the flu vaccination from their GP practice. These communications are designed to support local call and recall initiatives. It is important that all children are given early protection through the flu vaccine, and GP practices should aim to complete flu vaccination by the end of November at the latest.

15. Community pharmacies offering a flu vaccination service for adults will be required to do so in accordance with the Community Pharmacy Seasonal Influenza Vaccination Advanced service specification for 2020/21, which will be published at: www.england.nhs.uk/publication/community-pharmacy-seasonal-influenza-vaccine-service/

16. Planning for the school age programme should continue in the context of the current constraints of school closures and staff redeployment. The school age immunisation service specification has a requirement that, to provide early protection, the provider will complete the flu vaccination as early as possible after the flu vaccine becomes available and at the latest by 15 December for all eligible children. School aged vaccination services must actively invite 100% of eligible children. Providers will be required, if asked, to demonstrate that such an offer has been made.
Recommended vaccines for the national flu immunisation programme

17. Flu viruses change continuously and the World Health Organization (WHO) monitors the epidemiology of flu viruses throughout the world making recommendations about the strains to be included in vaccines. For further information on the strains for 2020/21, see the WHO website: www.who.int/influenza/vaccines/virus/recommendations/2020-21_north/en/


19. In summary these are:
   - for those aged 65 and over – the adjuvanted trivalent influenza vaccine (aTIV) (with the cell-based quadrivalent influenza vaccine (QIVc) offered if aTIV is unavailable)
   - for under-65s at risk, including pregnant women, offer QIVc or, as an alternative, the egg-grown quadrivalent influenza vaccine (QIVe)

20. The live attenuated influenza vaccine (LAIV) for children should be ordered through ImmForm from centrally purchased supplies and QIVe will be available to order for children in at risk groups aged less than 9 years old who are contraindicated to receive LAIV, in accordance with the letter referred to in paragraph 18. See: www.immform.dh.gov.uk

21. Children in at risk groups who are contraindicated to LAIV aged 9 years and over who access the vaccine through general practice should ideally be offered the QIVc from the practice’s locally procured vaccine stocks. GP practices offering QIVc to these children will be reimbursed by NHS England and NHS Improvement (NHSE/I). Where QIVc vaccine is unavailable, practices can either offer QIVe ordered through ImmForm from centrally purchased supplies (which will not be reimbursed), or their own locally procured QIVe which will be reimbursed by NHSE/I.

22. The DES and ES specifications state that in order for practices to receive payment for administration and reimbursement of vaccine they will need to use the specific flu vaccines recommended in the NHSE/I guidance.

23. The Community Pharmacy Seasonal Influenza Vaccination Advanced Service specification sets out the requirements under which community pharmacies may provide flu vaccinations to eligible adult patients, including detailing the specific flu vaccines which are recommended by NHSE and are reimbursable under this service.
Information and training resources for health professionals and PGDs

24. Healthcare practitioners should refer to the influenza chapter in ‘Immunisation against infectious disease’ (the “Green Book”) for further detail about clinical risk groups advised to receive flu immunisation and advice on contraindications and precautions for the flu vaccines. This can be found at:

25. Information for healthcare practitioners about the childhood flu programme and the inactivated flu vaccines, and links to training slide sets and flu e-learning programme will be available from: www.gov.uk/government/collections/annual-flu-programme and www.e-lfh.org.uk/programmes/flu-immunisation/

26. PHE will develop PGDs that will be available prior to commencement of the programme from: www.gov.uk/government/collections/immunisation-patient-group-direction-pgd and www.england.nhs.uk/publication/community-pharmacy-seasonal-influenza-vaccine-service/

Conclusion

27. We would like to take this opportunity to thank you all for your hard work in delivering the flu immunisation programme. Your continued efforts mean that we have some of the best flu vaccine uptake rates in Europe. This winter, more than ever, it is going to be a key intervention to reduce pressure on the NHS and social care.

28. We thank you for all your hard work in the most challenging of circumstances.

Yours sincerely,

Prof Chris Whitty
Chief Medical Officer
& Department of Health & Social Care
Chief Scientific Adviser

Prof Yvonne Doyle
Public Health England
Medical Director & Director for Health Protection

Prof Stephen Powis
NHS England & NHS Improvement, National Medical Director

Any enquiries regarding this publication should be sent to: immunisation@phe.gov.uk For operational immunisation queries, providers should contact their local screening and immunisation team.
Distribution list

General practices
Community pharmacies
Clinical commissioning groups clinical leaders
Clinical commissioning groups accountable officers
General Practitioners Committee
NHS England & NHS Improvement regional directors
NHS England & NHS Improvement regional directors of commissioning
NHS England & NHS Improvement regional directors of primary care & public health
NHS England & NHS Improvement heads of public health
NHS England & NHS Improvement heads of primary care
Sustainability and Transformation Partnership (STP) leads
PHE centre directors
PHE Screening and immunisation leads
NHS foundation trusts chief executives
NHS trusts chief executives
Heads of midwifery of NHS trusts
Chief pharmacists of NHS trusts
Local authority chief executives

For information:
Allied Health Professionals Federation
Community Practitioners and Health Visitors Association
Nursing and Midwifery Council
Royal College of Midwives
Royal College of Nursing
Academy of Medical Royal Colleges
Royal College of Anaesthetists
Royal College of Physicians
Royal College of Surgeons
Royal College of Obstetricians and Gynaecologists
Royal College of General Practitioners
College of Emergency Medicine
Faculty of Occupational Medicine
Royal College of Pathologists
Royal College of Ophthalmologists
Royal College of Paediatrics and Child Health
British Medical Association
Royal Pharmaceutical Society
Association of Pharmacy Technicians UK
Company Chemist’s Association
National Pharmacy Association
Pharmaceutical Services Negotiating Committee
Local Government Association
Association of Directors of Adult Social Services
Council of Deans of Health
General Medical Council
General Pharmaceutical Council
Faculty of Public Health
Association of Independent Multiple Pharmacies
UK Homecare Association (UKHCA)
Skills for Care
Association of Directors of Adult Social Services
Care Association Alliance
Care Provider Alliance
Hospice UK
Voluntary Organisations Disability Group
National Care Forum (NCF)
National Care Association (NCA)
Care England
ADASS (Association of Directors of Adult Social Services)
Local Government Association
Unison
## Summary table of which influenza vaccines to offer

<table>
<thead>
<tr>
<th>Eligible group</th>
<th>Type of flu vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At risk children aged from 6 months to less than 2 years</strong></td>
<td><strong>Offer QIVe.</strong></td>
</tr>
<tr>
<td></td>
<td>LAIV and QIVc are not licenced for children under 2 years of age.</td>
</tr>
<tr>
<td><strong>At risk children aged 2 to under 18 years</strong></td>
<td><strong>Offer LAIV</strong></td>
</tr>
<tr>
<td></td>
<td>If LAIV is contraindicated offer:</td>
</tr>
<tr>
<td></td>
<td>• QIVe to children less than 9 years of age.</td>
</tr>
<tr>
<td></td>
<td>• QIVc should ideally be offered to children aged 9 years and over who access the vaccine through general practice. Where QIVc vaccine is unavailable, GPs should offer QIVe.</td>
</tr>
<tr>
<td></td>
<td>• It is acceptable to offer only QIVe to the small number of children contraindicated to receive LAIV aged 9 years and over who are vaccinated in a primary school setting.</td>
</tr>
<tr>
<td><strong>Aged 2 and 3 years on 31 August 2020</strong></td>
<td><strong>Offer LAIV</strong></td>
</tr>
<tr>
<td><strong>All primary school aged children (aged 4 to 10 on 31 August 2020)</strong></td>
<td>If child is in a clinical risk group and is contraindicated to LAIV (or it is otherwise unsuitable) offer inactivated influenza vaccine (see above).</td>
</tr>
<tr>
<td><strong>At risk adults (aged 18 to 64), including pregnant women</strong></td>
<td><strong>Offer:</strong></td>
</tr>
<tr>
<td></td>
<td>• QIVc</td>
</tr>
<tr>
<td></td>
<td>• QIVe (as an alternative to QIVc)</td>
</tr>
<tr>
<td><strong>Those aged 65 years and over</strong></td>
<td><strong>Offer:</strong></td>
</tr>
<tr>
<td></td>
<td>• aTIV* should be offered as it is considered to be more effective than standard dose non-adjuvanted trivalent and egg-based quadrivalent influenza vaccines.</td>
</tr>
<tr>
<td></td>
<td>• QIVc is suitable for use in this age group if aTIV is not available.</td>
</tr>
<tr>
<td></td>
<td>* It is recommended that those who become 65 before 31 March 2021 are offered aTIV ‘off-label’.</td>
</tr>
</tbody>
</table>
All influenza vaccines marketed in the UK for the 2020 to 2021 season

<table>
<thead>
<tr>
<th>Supplier</th>
<th>Name of product</th>
<th>Vaccine type</th>
<th>Age indications</th>
<th>Ovalbumin content micrograms/dose</th>
<th>Contact details</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca UK Ltd</td>
<td>Fluenz® Tetra</td>
<td>Quadrivalent LAIV (live attenuated influenza vaccine) supplied as nasal spray suspension</td>
<td>From 24 months to less than 18 years of age</td>
<td>Less than 0.024 micrograms per 0.2 ml dose</td>
<td>0845 139 0000</td>
</tr>
<tr>
<td>GSK</td>
<td>Fluarix Tetra</td>
<td>QIve (standard egg-grown quadrivalent influenza vaccine), split virion, inactivated</td>
<td>From 6 months</td>
<td>Equal to or less than 0.05 micrograms per 0.5 ml dose</td>
<td>0800 221 441</td>
</tr>
<tr>
<td>MASTA</td>
<td>Quadrivalent Influenza vaccine ▼</td>
<td>QIve (standard egg-grown quadrivalent influenza vaccine), split virion, inactivated</td>
<td>From 6 months</td>
<td>Equal to or less than 0.05 micrograms per 0.5 ml dose</td>
<td>0113 238 7552</td>
</tr>
<tr>
<td>Sanofi Pasteur Vaccines</td>
<td>Quadrivalent Influenza vaccine ▼</td>
<td>QIve (standard egg-grown quadrivalent influenza vaccine), split virion, inactivated</td>
<td>From 6 months</td>
<td>Equal to or less than 0.05 micrograms per 0.5 ml dose</td>
<td>0800 854 430</td>
</tr>
<tr>
<td>Mylan</td>
<td>Quadrivalent Influvac® sub-unit Tetra ▼</td>
<td>QIve (standard egg-grown quadrivalent influenza vaccine), surface antigen, inactivated</td>
<td>From 3 years</td>
<td>Equal to or less than 0.1 micrograms per 0.5 ml dose</td>
<td>0800 358 7468</td>
</tr>
<tr>
<td>Seqirus UK Ltd</td>
<td>Flucelvax® Tetra ▼</td>
<td>QIVc (cell-grown quadrivalent influenza vaccine), surface antigen, inactivated</td>
<td>From 9 years</td>
<td>Egg-free</td>
<td>08457 451 500</td>
</tr>
<tr>
<td>Seqirus UK Ltd</td>
<td>Adjuvanted Trivalent Influenza Vaccine</td>
<td>aTIV (egg-grown trivalent influenza vaccine), surface antigen, inactivated, adjuvanted with MF59C.1</td>
<td>From 65 years</td>
<td>Equal to or less than 0.2 micrograms per 0.5 ml dose</td>
<td>08457 451 500</td>
</tr>
<tr>
<td>Sanofi Pasteur Vaccines</td>
<td>&quot;Trivalent Influenza Vaccine, High-Dose ▼</td>
<td>TIV-HD (high-dose egg-grown trivalent influenza vaccine), split virion, inactivated</td>
<td>From 65 years</td>
<td>Equal to or less than 1.0 micrograms per 0.5 ml dose</td>
<td>0800 854 430</td>
</tr>
</tbody>
</table>

*This vaccine will not be commissioned by NHSE/I and will not be reimbursed by NHSE/I in 2020/21.